IPHA Innate Pharma SA: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik innate-pharma.com (IPHA)

The leadership stability of Innate Pharma S.A. (IPHA) appears debatable until the EV/Sales ratio demonstrates the valuation-to-sales dynamics. The value 23406.88 reflects the latest metric reading, confirming the effectiveness of the model of transferring patents to tech giants in exchange for royalties. The company's strong position is bolstered by its status as a European expert in NK cells, which guarantees the high value of its innovative developments in immuno-oncology.

Nilai perusahaan marang pendapatan: Innate Pharma SA (IPHA) kanggo 23.11.2025 - 20.11.2026

innate-pharma.com - rincian analitis lan metrik utama (IPHA)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Innate Pharma S.A. IPHA
Sampel barang Innate Pharma S.A.

The EV/Sales multiple compares the total enterprise value of a business with its revenue, eliminating the impact of debt load on the valuation. Investors utilize this metric to identify overbought assets and prevent losses during coefficient corrections. Analyzing the historical EV/Sales trend captures the market's reaction to fundamental changes. For Innate Pharma S.A. (IPHA), a high valuation is justified by the prestige of the European scientific school. The intellectual capital of this oncology biotech firm generates the company's long-term value.

Analisis pesaing Innate Pharma S.A.

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IOVA|Multiplikator EV/Sales IMTX (Immatics)|Nilai bisnis marang pendapatan XNCR|compasstherapeutics.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Replimune Inc.|Lyell Immunopharma (LYEL) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP